Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
J Korean Med Sci
2012 Feb 01;272:228-30. doi: 10.3346/jkms.2012.27.2.228.
Show Gene links
Show Anatomy links
EML4-ALK fusion gene in Korean non-small cell lung cancer.
Jin G
,
Jeon HS
,
Lee EB
,
Kang HG
,
Yoo SS
,
Lee SY
,
Lee JH
,
Cha SI
,
Park TI
,
Kim CH
,
Jheon SH
,
Park JY
.
???displayArticle.abstract???
A fusion gene between echinoderm microtubule-associated protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK) has been identified in non-small cell lung cancers (NSCLCs). Although a few studies have evaluated EML4-ALK fusion genes in Korean NSCLCs, the prevalence of different EML4-ALK fusion variants has yet to be clearly assessed. Herein, we have examined the profiles of EML4-ALK fusion gene variants in Korean patients of NSCLCs. EML4-ALK fusion genes have been detected in 10 (6.0%) of 167 patients of NSCLCs and in 9 (7.4%) of 121 patients of adenocarcinoma. Of the 10 patients with fusion genes identified, 8 (80%) were E13;A20 (variant 1) and 2 (20%) were E6;A20, with an additional 33-bp sequence derived from intron 6 of EML4 (variant 3b). These results indicate that the profiles of EML4-ALK fusion gene variants in Korean patients of NSCLC may differ from those in other ethnic populations. Herein, we describe for the first time the profiles of EML4-ALK fusion variants of Korean patients with NSCLCs.
Fig. 1. Detection of EML4-4LK fusion genes by RT-PCR and sequencing. RT-PCR results of 10 positive cases with EML4-ALK fusion genes (A). Necleotide sequencing of the PCR products of variant 1 (B) and variant 3b (C).
Bronte,
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
2010, Pubmed
Bronte,
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
2010,
Pubmed
Dempke,
Targeted therapies for non-small cell lung cancer.
2010,
Pubmed
Horn,
EML4-ALK: honing in on a new target in non-small-cell lung cancer.
2009,
Pubmed
Jung,
Cancer statistics in Korea: incidence, mortality and survival in 2006-2007.
2010,
Pubmed
Jung,
Cancer statistics in Korea: incidence, mortality and survival in 2005.
2009,
Pubmed
Kim,
Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
2011,
Pubmed
Kim,
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
2012,
Pubmed
Koivunen,
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
2008,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Lee,
Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
2010,
Pubmed
Lee,
Characteristics of lung cancer in Korea, 1997.
2000,
Pubmed
Lynch,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
2004,
Pubmed
McDermott,
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
2008,
Pubmed
Parkin,
Global cancer statistics, 2002.
2005,
Pubmed
Sasaki,
The biology and treatment of EML4-ALK non-small cell lung cancer.
2010,
Pubmed
,
Echinobase
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
